0:00
My name is Bruce Schnepp,
and I'm from the Children's
Hospital of Philadelphia.
This lecture is
titled Vector Mediated
Immunoprophylaxis, which is a fairly
new concept in vaccine development.
I've been in this area of
study for over 15 years,
using this technology for the
development of an HIV vaccine.
0:18
For this lecture, I'm going
to focus on our efforts
to use vector mediated immunoprophylaxis as an HIV vaccine.
In our case, vector mediated
immunoprophylaxis simply
means that we're trying to
prevent disease by providing
antibodies to block infection.
A unique twist for us is how we
are delivering the antibodies.
So first, I'll introduce you to HIV
and sort of where we currently are
with progress towards a vaccine.
And I know that there
are other lectures
in this course that
discuss HIV in more detail,
so I'll keep this part brief.
I'll then introduce the concept of
vector mediated immunoprophylaxis
and the mechanics of how
it works, with emphasis
on how it differs from other
conventional vaccine strategies.
I'll then spend some time
discussing our path forward,
using this strategy to
develop an HIV vaccine.
This is sort of a case study that
takes you through some key animal
studies on mice and monkeys that
ultimately led us to clinical trial
on humans.
Finally, I'll discuss the future of
vector mediated immunoprophylaxis
with applications to
other difficult diseases
and end with highlighting a few of
the limitations of this strategy.
1:23
So here I'm showing you the
first report about HIV infection
that dates back to 1981.
That's 34 years ago.
So most of you probably
weren't even born at this time.
I, in fact, was in middle
school when this was published,
and a future and HIV
vaccine research was
the farthest thing from my mind.
